ZUCCHINI, Silvia
 Distribuzione geografica
Continente #
NA - Nord America 6.304
AS - Asia 2.718
EU - Europa 2.709
SA - Sud America 389
AF - Africa 49
OC - Oceania 4
Continente sconosciuto - Info sul continente non disponibili 1
Totale 12.174
Nazione #
US - Stati Uniti d'America 6.176
SG - Singapore 1.079
CN - Cina 883
PL - Polonia 675
RU - Federazione Russa 411
DE - Germania 405
BR - Brasile 328
UA - Ucraina 287
IT - Italia 274
HK - Hong Kong 226
GB - Regno Unito 223
TR - Turchia 190
FI - Finlandia 182
VN - Vietnam 138
CA - Canada 72
FR - Francia 59
SE - Svezia 50
IN - India 47
MX - Messico 42
ID - Indonesia 35
JP - Giappone 30
AR - Argentina 27
AT - Austria 26
CZ - Repubblica Ceca 26
ES - Italia 24
ZA - Sudafrica 24
BD - Bangladesh 21
LT - Lituania 17
NL - Olanda 17
IQ - Iraq 14
BE - Belgio 12
EC - Ecuador 10
IR - Iran 7
AE - Emirati Arabi Uniti 6
CO - Colombia 6
MA - Marocco 6
PK - Pakistan 6
CL - Cile 5
EG - Egitto 5
PT - Portogallo 5
SA - Arabia Saudita 5
VE - Venezuela 5
DO - Repubblica Dominicana 4
JO - Giordania 4
UZ - Uzbekistan 4
AU - Australia 3
DZ - Algeria 3
KE - Kenya 3
KR - Corea 3
PY - Paraguay 3
UY - Uruguay 3
AM - Armenia 2
AZ - Azerbaigian 2
BG - Bulgaria 2
BY - Bielorussia 2
DK - Danimarca 2
ET - Etiopia 2
HN - Honduras 2
IE - Irlanda 2
IL - Israele 2
JM - Giamaica 2
KZ - Kazakistan 2
LB - Libano 2
NP - Nepal 2
PA - Panama 2
PH - Filippine 2
RS - Serbia 2
SN - Senegal 2
TN - Tunisia 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AL - Albania 1
BA - Bosnia-Erzegovina 1
BH - Bahrain 1
CH - Svizzera 1
CI - Costa d'Avorio 1
CR - Costa Rica 1
DM - Dominica 1
GE - Georgia 1
GN - Guinea 1
GT - Guatemala 1
LA - Repubblica Popolare Democratica del Laos 1
LV - Lettonia 1
MD - Moldavia 1
MY - Malesia 1
NI - Nicaragua 1
NO - Norvegia 1
NZ - Nuova Zelanda 1
OM - Oman 1
PE - Perù 1
QA - Qatar 1
SR - Suriname 1
Totale 12.174
Città #
Ashburn 756
Fairfield 683
Warsaw 666
Woodbridge 645
Singapore 618
Houston 392
Beijing 354
Chandler 343
Jacksonville 313
Santa Clara 273
Seattle 261
Ann Arbor 256
Wilmington 243
Hong Kong 226
Munich 204
Cambridge 198
Los Angeles 128
New York 118
Ferrara 112
Nanjing 106
Izmir 102
Helsinki 87
Dallas 74
Princeton 71
San Diego 56
Shanghai 55
Milan 52
Ho Chi Minh City 51
Boardman 38
Washington 35
São Paulo 33
Turku 31
Brooklyn 30
Hanoi 29
Tokyo 29
Buffalo 28
Jakarta 28
Nanchang 25
London 24
Chennai 23
Chicago 23
Denver 23
Phoenix 23
Boston 22
Mexico City 22
Montreal 22
Hebei 21
Orem 21
Toronto 20
Moscow 19
Falkenstein 18
Frankfurt am Main 18
Poplar 18
Vienna 18
Bologna 17
Brno 17
Jiaxing 17
Johannesburg 17
San Francisco 17
Stockholm 17
Norwalk 16
Shenyang 16
The Dalles 16
Atlanta 15
Auburn Hills 14
Hefei 14
Dearborn 13
Falls Church 13
Mcallen 13
Ankara 12
Montréal 12
Tianjin 12
Brussels 11
Manchester 11
Mountain View 11
Rio de Janeiro 11
Amsterdam 10
Bremen 10
Changsha 10
Columbus 9
Ningbo 9
San Mateo 9
Dong Ket 8
Guangzhou 8
Guarulhos 8
Nuremberg 8
Redwood City 8
Roubaix 8
Wroclaw 8
Ardabil 7
Brasília 7
Da Nang 7
Jinan 7
Kunming 7
Olomouc 7
Zhengzhou 7
Belo Horizonte 6
Charlotte 6
Council Bluffs 6
Hangzhou 6
Totale 8.582
Nome #
Microdialysis of Excitatory Amino Acids During EEG Recordings in Freely Moving Rats 518
Is autopsy tissue a valid control for epilepsy surgery tissue in microRNA studies? 373
MicroRNA profiles in hippocampal granule cells and plasma of rats with pilocarpine-induced epilepsy - Comparison with human epileptic samples 347
Deletion of the Virion Host Shut-off Gene Enhances Neuronal-Selective Transgene Expression from an HSV Vector Lacking Functional IE Genes 347
Bystander effect on brain tissue of mesoangioblasts producing neurotrophins 335
Pharmacological characterization of the nociceptin/orphanin FQ receptor antagonist SB-612111 [(-)-cis-1-methyl-7-[[4-(2,6-dichlorophenyl)piperidin-1-yl]methyl]-6,7,8 ,9-tetrahydro-5H-benzocyclohepten-5-ol]: In vivo studies 274
[(pF)Phe4,Arg14,Lys15]N/OFQ-NH2 (UFP-102), a highly potent and selective agonist of the nociceptin/orphanin FQ receptor 232
FGF-2 Overexpression Increases Excitability and Seizure Susceptibility but Decreases Seizure-Induced Cell Loss 223
Effects of defective herpes simplex vectors expressing neurotrophic factors on the proliferation and differentiation of nervous cells in vivo 219
A pathogenetic hypothesis of Unverricht-Lundborg disease onset and progression 207
Decreased levels of neuropeptide Y5 receptor binding sites in two experimental models of epilepsy 206
Hippocampal FGF-2 and BDNF overexpression attenuates epileptogenesis-associated neuroinflammation and reduces spontaneous recurrent seizures. 205
Alterations in seizure susceptibility and in seizure-induced plasticity after pharmacologic and genetic manipulation of the Fibroblast Growth Factor-2 system 200
Personalized needles for microinjections in the rodent brain 195
Blockade of nociceptin/orphanin FQ-NOP receptor signalling produces antidepressant-like effects: pharmacological and genetic evidences from the mouse forced swimming test 188
Pharmacological profile of nociceptin/orphanin FQ receptors regulating 5-hydroxytryptamine release in the mouse neocortex 187
Endogenous nociceptin/orphanin FQ signalling produces opposite spinal antinociceptive and supraspinal pronociceptive effects in the mouse formalin test: Pharmacological and genetic evidences 183
Involvement of the neuropeptide nociceptin/orphanin FQ in kainate seizures 182
Brain-derived neurotrophic factor mRNA and protein are targeted to discrete dendritic laminas by events that trigger epileptogenesis 181
Involvement of the neuropeptide orphanin FQ/nociceptin in kainate and kindling seizures and epileptogenesis 181
A potential reservoir of immature dopaminergic replacement neurons in the adult mammalian olfactory bulb 178
Functional antagonism between nociceptin/orphanin FQ (N/OFQ) and corticotropin releasing factor (CRF) in the rat brain: evidence for involvement of the bed nucleus of the stria terminalis 177
Dendritic targeting of mRNAs for plasticity genes in experimental models of temporal lobe epilepsy 175
Gene Therapy Tools for Brain Diseases 174
Delayed epileptogenesis in nociceptin/orphanin FQ-deficient mice 170
Blockade of nociceptin/orphanin FQ transmission attenuates symptoms and neurodegeneration associated with Parkinson's disease 169
Immunotherapeutic activity of a recombinant combined gB-gD-gE vaccine against recurrent HSV-2 infections in a guinea pig model 166
Effects of [Nphe(1), Arg(14), Lys(15)] N/OFQ-NH2 (UFP-101), a potent NOP receptor antagonist, on molecular, cellular and behavioural alterations associated with chronic mild stress 165
Are the neurotrophic factors a suitable therapeutic target for the prevention of epileptogenesis? 163
Altered anxiety-related behavior in nociceptin/orphanin FQ receptor gene knockout mice 163
Mechanisms of action of CHF3381 in the forebrain 157
Antidepressant-like effects of the nociceptin/orphanin FQ receptor antagonist UFP-101: New evidence from rats and mice 154
Fibroblast Growth Factor-2 (FGF-2). 154
Localized overexpression of FGF-2 and BDNF in hippocampus reduces mossy fiber sprouting and spontaneous seizures up to 4 weeks after pilocarpine-induced status epilepticus 154
A Matter of Genes: The Hurdles of Gene Therapy for Epilepsy 153
In vitro and in vivo pharmacological characterization of the neuropeptide S receptor antagonist [D-Cys(tBu)5]neuropeptide S 153
Antipsychotic drugs counteract autophagy and mitophagy in multiple sclerosis 153
Temporal lobe epilepsy model, neural stem cells and gene therapy 152
Pro-nociceptin/orphanin FQ and NOP receptor mRNA levels in the forebrain of food deprived rats 152
Red blood cells as delivery system for recombinant HSV-1 glycoprotein B: Immunogenicity and protection in mice 150
Properties and maturation of adult-generated dopaminergic neurons in the mammalian olfactory bulb 145
Replication-defective herpes simplex virus vectors for neurotrophic factor gene transfer in vitro and in vivo 145
Heparan sulfate proteoglycan binding by herpes simplex virus type 1 glycoproteins B and C, which differ in their contributions to virus attachment, penetration, and cell-to-cell spread 144
Implication of sestrin3 in epilepsy and its comorbidities 143
Herpes Simplex Virus Type 1 (HSV-1) Uracil-DNA Glycosylase: Functional Expression in Escherichia coli, Biochemical Characterization, and Selective Inhibition by 6-(p-n-Octylanilino)Uracil 139
Bradykinin B2 receptors increase hippocampal excitability and susceptibility to seizures in mice 137
Dynorphin and Nociceptin/Orphanin FQ (N/OFQ). 132
Different patterns of induction of fibroblast growth factor-2 and brain-derived neurotrophic factor messenger RNAs during kindling epileptogenesis, and development of a herpes simplex vector for fibroblast growth factor-2 gene transfer in vivo 128
HERPES-SIMPLEX VIRUS TYPE-1 URACIL-DNA GLYCOSYLASE - CLONING AND CHARACTERIZATION 123
Increased susceptibility to kainate seizures and decreased seizure-induced cell loss in transgenic mice overexpressing fibroblast growth factor-2 122
Inhibition of human immunodeficiency virus reactivation from latency by a tat transdominant negative mutant 116
Low-dose 7,8-Dihydroxyflavone Administration After Status Epilepticus Prevents Epilepsy Development 106
Immunotherapeutic activity of a recombinant glycoprotein vaccine aganst recurrent genital herpes in a guinea pig model. 106
Brain interstitial nociceptin/orphanin FQ levels are elevated in Parkinson’s disease 105
Localized delivery of fibroblast growth factor-2 and brain-derived neurotrophic factor reduces spontaneous seizures in an epilepsy model 104
Impairment of GABA release in the hippocampus at the time of the first spontaneous seizure in the pilocarpine model of temporal lobe epilepsy 103
null 97
Increased extracellular levels of glutamate in the hippocampus of chronically epileptic rats 97
Gene therapy of the nervous system by herpes virus vectors 95
Inhibition of human immunodeficiency virus reactivation from latency by tat antisense RNA and a tat transdominant negative mutant 95
Improvement of HSV-1 based amplicon vectors for a safe and long-lasting gene therapy in non-replicating cells 95
The NLRP3 Inflammasome in Neurodegenerative Disorders: Insights from Epileptic Models 94
null 94
null 94
null 93
null 92
Lack of Direct Effects of Neurotrophic Factors in an In Vitro Model of Neuroinflammation 90
null 89
null 89
null 89
Molecular approaches to inhibit HIV-1 tat expression and functions 88
Circulating microRNAs and isomiRs as biomarkers for the initial insult and epileptogenesis in four experimental epilepsy models: The EPITARGET study 88
Increased excitability in tat-transgenic mice: role of tat in HIV-related neurological disorders 79
Gene therapy for epilepsy targeting neuropeptide Y and its Y2 receptor to dentate gyrus granule cells 79
Sampling Cerebrospinal Fluid and Blood from Lateral Tail Vein in Rats during EEG Recordings 73
Possible Approaches of Gene Therapy of AIDS. 71
Neuroprotective activity of CHF3381, a putative N-methyl-D-aspartate receptor antagonist 70
Identification of miRNAs differentially expressed in human epilepsy with or without granule cell pathology 69
Viral Vector-Based Gene Therapy for Epilepsy: What Does the Future Hold? 68
Implication of fibroblast growth factors in epileptogenesis-associated circuit rearrangements. 59
null 43
Totale 12.303
Categoria #
all - tutte 52.372
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 2.445
Totale 54.817


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021609 0 0 0 0 0 100 43 113 38 157 113 45
2021/2022742 31 94 61 24 27 28 47 42 20 48 69 251
2022/2023734 74 44 48 75 119 101 38 77 100 4 40 14
2023/2024881 41 46 41 12 48 222 89 97 66 62 50 107
2024/20252.055 55 47 152 114 215 264 86 109 324 157 253 279
2025/20262.928 654 194 397 756 830 97 0 0 0 0 0 0
Totale 12.303